Emergence of KPC-31, a KPC-3 Variant Associated with Ceftazidime-Avibactam Resistance, in an Extensively Drug-Resistant ST235 Pseudomonas aeruginosa Clinical Isolate-Reference-Cited by-同舟云学术

Emergence of KPC-31, a KPC-3 Variant Associated with Ceftazidime-Avibactam Resistance, in an Extensively Drug-Resistant ST235 Pseudomonas aeruginosa Clinical Isolate

Published:2022-11-15 Issue:11 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Faccone Diego¹²,de Mendieta Juan M.¹,Albornoz Ezequiel¹,Chavez Magali¹,Genero Fabiana³,Echegorry Mariano¹,Ceriana Paola¹,Mora Andrea⁴,Seah Christine⁵,Corso Alejandra¹,Melano Roberto G.⁵⁶^ORCID,Pasteran Fernando¹

Affiliation:

1. Servicio Antimicrobianos, Instituto Nacional de Enfermedades Infecciosas (INEI) - ANLIS “Dr. Carlos G. Malbrán”, Buenos Aires, Argentina

2. Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina

3. Servicio de Microbiología, Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia - FLENI, Buenos Aires, Argentina

4. Servicio de Infectología, FLENI, Buenos Aires, Argentina

5. Public Health Ontario Laboratory, Toronto, Ontario, Canada

6. University of Toronto, Toronto, Ontario, Canada

Abstract

A ceftazidime-avibactam-resistant KPC-producing Pseudomonas aeruginosa strain was isolated in Argentina from a tracheal aspirate. The patient was treated with ceftazidime-avibactam in combination with other agents for 130 days.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00648-22

Reference19 articles.

1. Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections

2. Detection of an international multiresistant clone belonging to sequence type 654 involved in the dissemination of KPC-producing Pseudomonas aeruginosa in Argentina

3. Global emergence of the widespread Pseudomonas aeruginosa ST235 clone

4. Combination of MexAB-OprM overexpression and mutations in efflux regulators, PBPs and chaperone proteins is responsible for ceftazidime/avibactam resistance in Pseudomonas aeruginosa clinical isolates from US hospitals

5. Emergence of a KPC-90 Variant that Confers Resistance to Ceftazidime-Avibactam in an ST463 Carbapenem-Resistant Pseudomonas aeruginosa Strain

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. KPC variants conferring resistance to ceftazidime-avibactam in Pseudomonas aeruginosa strains;Microbiological Research;2024-12

2. Complex evolutionary trajectories in vivo of two novel KPC variants conferring ceftazidime-avibactam resistance;International Journal of Antimicrobial Agents;2024-09

3. Impact of chromosomally encoded resistance mechanisms and transferable β-lactamases on the activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa;Journal of Antimicrobial Chemotherapy;2024-07-29

4. First report of KPC variants conferring ceftazidime-avibactam resistance in Colombia: introducing KPC-197;Microbiology Spectrum;2024-06-04

5. Pseudomonas aeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID/ISARPAE Group;Clinical Microbiology and Infection;2023-12